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Purpose: The Schirmer’s test is commonly used in the clinic for the diagnosis of dry eye disease by measuring tear volume.
This report describes a procedure which can be used to recover tears from the Schirmer strip for the measurement of
multiple tear cytokines as well as matrix metalloproteinases (MMPs) by Luminex technology.
Methods: Cytokine and MMP recovery was determined by using spiked Schirmer strips presoaked with known cytokines
or MMPs prepared in PBS with 1% BSA. In a clinical study, tears were collected from 5 subjects using Schirmer strips.
Strips were stored on ice immediately after removal from the subject and stored dry at −20 °C for 16–24 h. Cytokines
were extracted from the Schirmer strip in 0.5 M NaCl with 0.5% Tween-20. Concentrations of cytokines and MMPs in
collected tear samples were analyzed by Luminex using both a 10-cytokine and a 5-MMP kit.
Results: The standard curves for the assay in both the kit assay buffer and extraction buffer were identical for 9 of the 10
cytokines and all 5 MMPs. In the clinical sample all the cytokines (interleukin 1α [IL-1α], IL-1β, IL-1ra, IL-4, IL-6, IL-8,
IL-10, IL-13, monocyte chemotactic protein-1 [MCP-1], and tumor necrosis factor-α [TNF-α]) and 5 MMPs (MMP-1,
MMP-2, MMP-7, MMP-9, and MMP-10) tested were detected in at least 50% of the 10 subject samples. Recoveries from
extracted Schirmer strips were >60% for 8 of the 10 cytokines and all MMPs.
Conclusions: Numerous cytokines and MMPs were detected in the tear samples collected using the Schirmer strip,
including many that have been implicated in ocular surface disease. This procedure may be used to evaluate the cytokine
and MMP content in tear samples in clinical studies, especially for the evaluation of dry eye therapeutics. Because the
Schirmer test is routine in the assessment of dry eye, this method offers the opportunity to evaluate both the quantity and
quality of the tears.
Tear samples are being used with increasing frequency to
detect biomarkers of normal and diseased states of the ocular
surface [1-3], including allergy [4], and dry eye [5,6]. While
use of ELISA is common, the employment of multiplex bead
[7,8], multi-array [9], and proteomic [10-12] technology has
enhanced the use of collected tears by allowing for analysis
of  small  sample  volumes  while  increasing  the  number  of
detectable targets.
The  most  commonly  reported  method  to  collect  tear
samples for biomarker analysis is by capillary tube [13-15].
In  addition,  it  has  been  reported  that  cellulose  acetate
absorbent filters [16], a Weck Cell Sponge [4], and an water
eye  wash  [17]  have  been  used  to  collect  tear  samples.
However, Schirmer strips are routinely used to measure the
tear volume for the clinical assessment of dry eye disease. It
would be of added value if, rather than discarding the strips
after the assessment, the tear components could be eluted from
these  strips  and  used  for  the  measurement  of  known
biomarkers,  such  as  proinflammatory  cytokines  and  other
inflammatory mediators.
Cytokines, chemokines, and matrix metalloproteinases
(MMPs) have been considered as potential biomarkers for
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ocular surface inflammation. Indeed, increased levels of pro-
inflammatory cytokines such as interleukin 1 (IL-1), IL-6, and
tumor necrosis factor-α (TNF-α), chemokines such as IL-8
and monocyte chemotactic protein-1 (MCP-1), and matrix
metalloproteinase-9 (MMP-9) have been demonstrated to be
associated with ocular surface diseases [1,4,18,19] including
dry eye [20,21].
The Luminex multi-analyte profiling assay system is a
technology based on the principle of flow cytometry. The
system  allows  one  to  simultaneously  measure  numerous
analytes in a single microplate well, using very small sample
volumes  [7]  while  achieving  excellent  correlations  to
individual ELISA for many cytokines [22]. This system has
been  successfully  used  to  study  the  effect  of  anti-
inflammatory agents on cytokine release profiles of cultured
human ocular cells [23,24]. Recently, Luminex has also been
used to measure the cytokine content in tear samples collected
with capillary tubes [5]. The results from the current study
demonstrate  that  numerous  cytokines  and  MMPs  can  be
detected by Luminex from the tear samples collected using a
Schirmer strip.
METHODS
Reagents: TearFlo™ Schirmer filter paper strips with an inked
ruler  were  obtained  from  Contacare  Ophthalmics  &
Diagnostics (Gujarat, India). Human multiplex-cytokine and
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1056MMP kits were from Millipore (Billerica, MA). All other
reagents were purchased from standard commercial sources
and were of the highest available purity.
Standard curve of solution volume to Schirmer strip reading:
To  calculate  millimeters  of  wetting  with  volume  of  tears
collected,  a  standard  curve  was  developed.  Phosphate-
buffered saline (PBS; 2.5, 5, 7.5, 10, 15, 20, 25, or 30 µl) was
transferred to the rounded end of a Schirmer strip and the strip
was placed in a 2-ml eppendorf tube lying flat on the bench
surface. After 1 min the measurement as millimeter (mm)
wetting was recorded. This measurement was repeated a total
of 3 times for each volume tested, and a standard curve of
volume to Schirmer strip reading was generated.
Clinical subjects: The clinical study protocol was approved
by the Southwest Independent Institutional Review Board and
was  conducted  in  accordance  with  21  Code  of  Federal
Regulations for Clinical Trials (CFR) Parts 812, 50, 54, and
56,  applicable  Bausch  +  Lomb  Standard  Operating
Procedures, and the Declaration of Helsinki. All five healthy
volunteers gave informed consent and they were assessed for
eligibility. Inclusion criteria were as follows: be 18 years or
older and have full legal capacity to volunteer, have no allergic
conjunctivitis, not be using any topical ocular medications, no
contact lens wear or ophthalmic drop use 8 h before their study
visit, be willing and able to follow instructions, and have
signed  a  statement  of  informed  consent.  Subject
discontinuation criteria were: adverse effects, other ocular
complications, subject non-compliance, subject request, or
subject found to be ineligible during study participation. The
age,  gender,  Ocular  Surface  Disease  Index  (OSDI),  and
Schirmer strip measurements for the five subjects are shown
in Table 1.
Tear sample collection: The Investigator, with gloves, placed
a Schirmer strip over the lid margin at the junction of the
lateral and middle thirds of the lower eyelids and kept in place
for  5  min  while  subjects  closed  their  eyes  without  an
anesthetic. The Schirmer strips were removed with gloves and
tear volume in millimeters was recorded. Each Schirmer strip
was placed into a sterile 2-ml centrifuge tube, stored on ice
for 20 min to 1 h, and then stored at −20 °C until processed.
Preparation of spiked cytokine and MMP Schirmer strips: To
determine  the  feasibility  and  sensitivity  of  the  kits  for
recovering cytokines and MMPs from the Schirmer strips, the
low internal quality controls (QC-1) from each cytokine and
MMP kit were prepared as described in the kit assay protocol.
Twenty µl of each QC-1 was aliquotted to a Schirmer strip,
allowed to flow for 1 min and the strip was transferred to a 2-
ml eppendorf tube and frozen at −20 °C (24 h). For percent
recovery, 20 µl of each QC was simultaneously aliquotted into
a separate eppendorf tube and frozen at −20 °C (24 h). Each
experiment for the strips and diluted frozen samples were
prepared in triplicate.
Extraction  of  cytokines  and  MMPs  from  Schirmer  strips:
Assay buffer (200 µl) of the analyte kit containing 1% BSA
(BSA) in phosphate buffered saline (PBS) with sodium azide
as a preservative or extraction buffer containing 0.5 M NaCl
and 0.5% Tween-20 [25] was added to each 2-ml centrifuge
tube and incubated for 3 h at ambient temperature on a rocker
(VWR,  West  Chester,  PA),  and  then  stored  on  ice  upon
completion. The strip was transferred to a new 2-ml tube and
residual liquid was removed by pinching the strip at the 25-
mm mark in the sealed tube cap, and the sample was then
centrifuged (Microfuge R, Beckman, Palo Alto, CA) at ~100×
g for 10 s. This liquid was combined with stored extraction
buffer. The Schirmer strips were discarded. Each 20-µl frozen
sample was diluted in 180 µl assay or extraction buffer and
treated to the same extraction regimen as described for the
strips.
Standard  curve  comparison:  To  ensure  there  was  no
interference in the assay from the extraction buffer, standard
curves were prepared in parallel in the kit assay buffer and
extraction buffer and were assessed on the same assay plate.
Standard  curves  were  generated  using  the  kit  internal
standards vs maximum fluorescence intensity (MFI) and were
graphically represented using Sigmaplot software (Systat, San
Jose, CA).
Statistical analysis of cytokine and MMP standard curves in
both the assay buffer and extraction buffer: Comparison of
each individual standard concentration points prepared in both
the kit assay buffer and extraction buffer was performed using
a  one-way  ANOVA-Tukey-Kramer  test  (JMP  7  software;
TABLE 1. CLINICAL SUBJECT DATA.
Subject
number
Age Gender OSDI* Severity based on
OSDI
Schirmer OD Schirmer OS
1 54 F 37.5 1 10 15
2 41 F 25 1 6 7
3 26 M 0 0 28 32
4 53 F 20.8 1 6 14
5 25 F 0 0 35 35
               *OSDI scale [34]: Normal (0) 0–20.7; Mild (1) 20.8–41.6; Moderate (2) 41.7–72.9; Severe (3) 73–100.
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1057SAS Institute, Cary, NC) and for each standard concentration
point  p<0.05  was  pre-determined  to  be  statistically
significant.
Luminex multiplex cytokine and MMP analysis: Cytokine and
MMP content in both the spiked and tear extracted strips were
analyzed  using  multiplex  Luminex  technology  [7,26]  and
performed according to the manufacturer's instructions with
all  kit  reagents,  assay  and  wash  buffers.  Analysis  was
performed on cytokines and MMPs listed in Table 2 and Table
3. Briefly, 25 µl of each sample extract was incubated with
antibody-coated capture beads overnight at 4 °C on a Titer
Plate Shaker (Lab-Line Instrument, Park, IL). Washed beads
were  further  incubated  with  biotin-labeled  anti-human
cytokine antibodies for 1 h at room temperature followed by
incubation with streptavidin-phycoerythrin for 30 min and
followed by an additional wash step. Beads were resuspended
in Luminex flow buffer for 5 min and samples were analyzed
using Luminex 200™ (Luminex, Austin, TX).
Determination of percent recovery of cytokine from spiked
Schirmer strips: For percent recovery analysis the median
fluorescence  intensity  (MFI)  was  used  to  obtain  the
concentration of each cytokine in pg/ml based on the standard
curve of each cytokine assayed by Luminex. Concentrations
were  estimated  using  the  Statlia  software  (Brendan
Technologies, Inc., Carlsbad, CA). Each sample was tested in
duplicate  and  resulting  concentrations  were  averaged.
Samples with concentrations of cytokines outside the assay
limits, as determined from the Statlia analysis, were excluded
from  further  analysis.  Cytokines  recovered  from  both  the
diluted samples and spiked Schirmer strips were compared to
the  nominal  concentrations  of  the  QC-1  control.  Percent
recovery for each sample was determined by the equation:
Percent  recovery=(Mean  of  recovered  sample  analyte
concentration/nominal  analyte  concentration)*100.  The
nominal analyte concentration was determined by performing
the QC-1 control according to the kit instructions.
TABLE 2. PERCENT RECOVERY OF CYTOKINES DILUTED IN BUFFER OR EXTRACTED FROM SPIKED SCHIRMER STRIPS.
  Recovery in assay buffer Recovery in extraction buffer  
Cytokine Diluted sample
(Mean/SE)
Extracted SS sample
(Mean/SE)
Diluted sample
(Mean/SE)
Extracted SS sample
(Mean/SE)
IL-1α 77.8±4.7 66.9±4.0 84.6±5.6 79.8±4.2
IL-1β 81.5±6.2 59.0*±3.8 84.5±4.3 82.9±4.6
IL-1rα 86.0±4.5 67.7±3.5 74.5±5.3 68.5±3.5
IL-4 96.9±8.7 37.2±3.5 62.9±5.1 6.7±1.4
IL-6 82.5±3.5 68.2±2.7 78.2±3.3 67.1±3.3
IL-8 91.1±5.3 68.3*±4.3 89.3±4.9 76.8±4.2
IL-10 83.0±3.2 30.5*±2.8 BLD BLD
IL-13 83.8±5.0 49.7*±2.6 85.2±8.2 29.4*±3.5
MCP-1 90.1±4.4 77.7±4.1 87.6±4.4 84.2±2.5
TNF-α 81.9±5.8 62.8±2.8 91.5±7.0 65.1*±4.3
        *p<0.05 versus cytokine diluted in same assay buffer and calculated from same buffer standard curve. BLD: Below the limit of
        detection. n=10 for all data.
TABLE 3. PERCENT RECOVERY OF MMPS DILUTED IN BUFFER OR EXTRACTED FROM SPIKED SCHIRMER STRIPS.
 
MMP Diluted sample
(Mean/SE)
Extracted SS sample
(Mean/SE)
Diluted sample
(Mean/SE)
Extracted SS sample
(Mean/SE)
MMP-1 92.1 ± 7.8 88.9 ± 4.0 91.1 ± 9.7 78.5 ± 7.5
MMP-2 94.3 ± 3.1 89.4 ± 5.1 86.8 ± 3.9 81.4 ± 5.0
MMP-7 93.6 ± 5.0 68.2* ± 5.1 86.7 ± 2.5 76.3 ± 17.3
MMP-9 96.7 ± 9.2 86.1 ± 8.5 100.2 ± 8.3 84.5 ± 6.8
MMP-10 87.0 ± 6.3 79.3 ± 2.7 94.4 ± 7.5 77.2 ± 3.4
        *p<0.05 versus MMP from diluted sample with extracted and concentration calculated from equivalent buffers. n=10 for all data.
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Recovery in assay buffer Recovery in extraction buffer  Statistical analysis of spiked cytokine from Schirmer strips:
Comparison of the recovered sample from spiked Schirmer
strips to the sample diluted in buffer was performed using a
one-way ANOVA-Tukey-Kramer test (JMP 7) and a p<0.05
was pre-determined to be statistically significant.
Determination  of  pg/mlmeasured  in  tears  obtained  via
Schirmer  strips:  The  amount  of  each  cytokine  or  MMP
measured in the tears extracted from Schirmer strips was
expressed   as   total   recovery   in   picograms  per  milliliter
(pg/ml)  as follows:  First,  the calculated sample in  pg/ml was
multiplied  by the total  extraction sample  volume (0.2 ml) to
give total  pg  in the extracted sample. Final pg/ml based upon
Schirmer    volume   was    calculated    by   dividing    total   pg
extracted  by  the  calculated  Schirmer  strip  volume  (pg/µl)
and  multiplying by 1,000.   Means and  standard errors (SE)
of   the 10  samples  were  determined for each  cytokine and
MMP.
RESULTS
Standard curve of solution volume to Schirmer strip reading:
This experiment was designed to determine the relationship
between the reading on the Schirmer strip as millimeter (mm)
and actual volume (µl) of the PBS solution absorbed onto the
strip  over  a  period  of  one  minute.  Although  a  linear
relationship  was  found,  the  tear  volume  measurement  in
millimeters did not equate to the same number for microliters
(Figure 1). This standard curve was used to determine the
actual volume of the tears on the clinical Schirmer strips.
Luminex  standard  curves  in  standard  assay  and  elution
buffers:  All  the  standard  concentration  points  on  curves
generated in the extraction buffer for all cytokines and MMPs,
except  for  IL-10,  were  statistically  comparable  to  the
concentration points generated in the kit assay buffer. For
IL-10,  all  standard  concentrations  except  for  the  lowest
Figure 1. Graph of volume versus Schirmer strip measurement. Each
data  point  represents  the  mean  and  standard  deviation  from  3
individual experiments. The line was determined by linear regression
and the correlation coefficient was 0.999.
concentration  were  significantly  lower  in  the  extraction
buffer.  Graphs  for  IL-10,  2  major  pro-inflammatory
cytokines, IL-1α, and IL-6, and MMPs 2 and 9 are shown in
Figure 2.
Recovery of cytokines and MMPs from spiked Schirmer strips:
For  these  experiments,  and  the  clinical  Schirmer  strip
extractions, identical 10 cytokine and 5 MMP kits were used.
In  these  experiments  the  recovery  for  each  20-µl  sample
extracted from a Schirmer strip was compared to the recovery
equal volume in solution. The percent recoveries represent the
amount of diluted or extracted sample as compared to the
theoretical recovery for each cytokine with each buffer. For
the assays performed with kit assay buffer, the recoveries of
IL-1β, IL-8, IL-10, and IL-13 were significantly lower in the
extracted strips as compared to the diluted samples (Table 3).
For the assays performed with the extraction buffer both IL-13
and TNF-α had significantly lower extracted strip recoveries,
while IL-10 was below the limit of detection in this buffer and
could not be analyzed. Of the extracted MMP strip samples,
only MMP7, extracted in assay buffer had a significantly
lower recovery.
Recovery  of  cytokines  and  MMPs  from  clinical  Schirmer
strips:  Of  the  10  samples  tested  in  this  study,  all
concentrations for the 10 cytokines tested were determined to
be within the maximum reportable concentration except for 3
of the samples tested for IL-1ra (Figure 3). These 3 samples
were re-tested at a 10-fold dilution in extraction buffer for
IL-1ra only and the determined concentrations were found to
be within the reportable range. Only 50% of samples for TNF-
α were above the minimum detectable concentration for this
assay, while all samples contained IL-1α, IL-1ra, IL-8 and
MCP-1. Cytokines IL-6 and IL-13 were recovered in 80% of
sample, IL-4 and IL-10 in 70% and IL-1β in 60%. Of the 5
MMPs tested in this study MMP-7, MMP-9, and MMP-10
were recovered in all the samples, while MMP-1 (70%) and
MMP-2 (80%) were recovered in most of the samples (Figure
4). Only the samples within the reportable range of the assay
were used for determination of calculated recoveries for these
cytokines.
DISCUSSION
Researchers are using ever-expanding platforms of multiplex
technology,  which  allow  for  the  use  of  minimal  sample
volumes from tears to identify biomarkers associated with dry
eye disease (DED) [6,9]. Schirmer’s test has been considered,
rightly  or  wrongly  [27,28],  as  a  “gold  standard”  for  the
assessment of dry eye conditions, and is therefore a key test
in both the clinical office setting and clinical trials for various
treatment  modalities.  In  addition  to  its  traditional  use  of
determining  tear  volume,  this  test  also  provides  clinical
samples  which,  until  recently,  have  not  been  commonly
assessed for comprehensive biologic alterations to the tear
film in ocular surface disease. In part, this has been because
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for preparations in kit assay buffer: closed circles with solid line or extraction buffer: open circles with dashed line. *p<0.05 versus equivalent
concentration in assay buffer.
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to the amount needed for biologic assays. However, with the
advance  of  technologies  which  facilitate  meaningful
assessments in small-volume clinical samples, the potential
for  additional  assessment  from  this  standard  test  is  very
attractive. Recently, methods employed to collect tears from
subjects include microcapillary tubes [8], polyvinyl acetate
sponges [4], and acetate filters [16]. While each of these
methods has its advantages, they would be an additional step
in the clinical setting, costing additional time to both patient
and clinical researcher. Furthermore, as both the Schirmer
strip and the other techniques remove tears from the ocular
surface, if both were performed; either procedure followed by
the other would compromise the second test. Therefore, the
use  of  Schirmer  strips  for  additional  biomarker  analysis,
including cytokines, chemokines, and MMPs, would be of
immense  benefit.  Schimer  strips  have  been  used  to
successfully recover single analytes including eotaxins [25],
cystatins  [29],  secretory  IgA  [30],  and  Vitamin  C  [31].
However, a comprehensive evaluation using Schirmer strips
for the measurement of multiple cytokines as well as MMPs
has not been previously described.
The Luminex multiplex platform is ideally suited for the
detection of biomarkers from tear samples [6,8,28]. In the
study presented here, Luminex kits were tested for capability
of each kit to detect 10 cytokines and 5 MMPs recovered from
Figure  3.  Concentrations  of  10
cytokines  extracted  from  clinical
Schirmer strips. All data are expressed
as mean±SEM.
Figure  4.  Concentrations  of  5  MMPs
extracted from clinical Schirmer strips.
All data are expressed as mean±SEM.
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prototype extraction buffer containing high salt and detergent
does not interfere with the reproducible generation of standard
curves  for  14  of  the  15  analytes  tested.  When  the  actual
recovered  sample  from  the  spiked  Schirmer  strip  was
compared to the quantity recovered from the diluted control,
both IL-10 and IL-13 were poorly recovered in both the assay
and extraction buffers. It is unlikely that the observed poor
recoveries of IL-10 and IL-13 were due to the buffer system
since the two buffers tested in the current study were very
different, one contains 0.5% Tween-20 and other one does not.
Furthermore, cytokine kits from two other vendors were also
tested and generated somewhat less efficient recoveries for
most cytokines (data not shown). These findings suggest that
a simple wetting of the strips may be sufficient to recover the
cytokines and MMPs, and as our goal was to maximize the
recovery of the most relevant pro-inflammatory cytokines,
including IL-1, IL-6 and IL-8, the methods employed and the
kit used in our studies were highly suitable for this purpose.
Finally,  clinical  Schirmer  strip  tear  samples  obtained
from 5 subjects were tested for 10 cytokines of which 9 were
recovered  in  >50%  of  the  samples.  However,  while  our
clinical sample size was limited to 5 subjects, TNF-α was still
below  the  limit  of  detection  for  half  of  these  samples,
suggesting either an inability of this cytokine to be detected
using  our  methodology  or  that  minimal  quantities  of  this
cytokine  were  present  in  our  clinical  test  samples.
Interestingly, IL-10, which was poorly recovered from spiked
strips, was recovered in detectable quantities in most clinical
samples.  Additional  work  would  be  needed  to  further
understand this phenomenon. In addition, all 5 MMPs were
efficiently recovered from these samples, including MMP-9,
which has been demonstrated to be involved in corneal barrier
disruption in experimental dry eye models [32,33]. Future
efforts  will  include  the  assessment  of  extraction  buffer
characteristics  with  regard  to  recovery  and  detection  of
cytokines,  with  emphasis  on  the  primary  pro-  and  anti-
inflammatory cytokines and MMPs that may be affected in
dry eye conditions. In addition, kits from multiple vendors
may be used to develop our ability to detect the key cytokines
in clinical samples.
Tear reflection is very common with Schirmer's test due
to the strong irritation by the strip. By looking at Table 1,
subject 5 and 3 might have tear reflection during the test, as
their  Schirmer's  scores  were  abnormally  high.  With  tear
reflection, the cytokine and MMP can be easily diluted. Tear
reflection was not considered in this study as the focus was
more  for  the  merits  of  the  technical  development  on  the
cytokine recovery from the Schirmer strip than the actual
concentrations  of  the  cytokines  recovered  and  the  tear
collection. However, this is a very important issue which
should  be  considered  when  collecting  tear  samples  and
analyzing the cytokine concentration.
In summary, results from the current study demonstrated
that numerous cytokines as well as several MMPs can be
recovered from the Schirmer strip and quantitatively analyzed
by Luminex technology. Because Schirmer’s test is routinely
used  for  the  assessment  of  dry  eye  and  inflammation  is
recognized as a potential mechanism of dry eye or therapeutic
target, this method offers the opportunity to evaluate both the
quantity and quality of the tears.
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